Go to deals
Healthcare

Protalix BioTherapeutics, Inc. has completed a private stock placement

Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.

Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Ruben  Eblagon

Ruben Eblagon

Principal

Tel Aviv, Israel
Oaklins Rosario
 Boaz  Levi

Boaz Levi

Partner

Tel Aviv, Israel
Oaklins Rosario
 Olga  Geyber

Olga Geyber

Support

Tel Aviv, Israel
Oaklins Rosario

Related deals

Improve International Ltd. has been acquired by RJD Partners
Healthcare | TMT

Improve International Ltd. has been acquired by RJD Partners

Benchmark Holdings Plc. has sold Improve International Ltd. to RJD Partners.

Learn more
Zemach Hammerman Ltd. has issued bonds
Real Estate

Zemach Hammerman Ltd. has issued bonds

Zemach Hammerman Ltd. has raised funds to refinance the company for further development.

Learn more
Mutigny Resort Hotel has raised funds to construct a new 4-star hotel in Champagne
Consumer & Retail | Real Estate

Mutigny Resort Hotel has raised funds to construct a new 4-star hotel in Champagne

Mutigny Resort Hotel (MRH) has raised funds to construct a new 4-star hotel in Champagne. This involved agreements with the promoter, Artec Groupe, the operator, Loisium Wine & Spa Hotels, bank debt with Caisse d'Epargne Grand-Est Europe, Banque Postale and Arkea, and equity with La Banque des territoires, Merimee and Artec Groupe.

Learn more